Zacks Research Analysts Increase Earnings Estimates for JAZZ

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Stock analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Tuesday, March 18th. Zacks Research analyst S. Ganoria now expects that the specialty pharmaceutical company will post earnings per share of $3.51 for the quarter, up from their prior estimate of $3.17. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q2 2025 earnings at $4.70 EPS, Q3 2025 earnings at $5.30 EPS, Q4 2025 earnings at $5.51 EPS, FY2025 earnings at $19.02 EPS, Q1 2026 earnings at $3.13 EPS, Q2 2026 earnings at $4.79 EPS, Q3 2026 earnings at $5.84 EPS, Q4 2026 earnings at $5.90 EPS, FY2026 earnings at $19.66 EPS and FY2027 earnings at $20.50 EPS.

Other analysts have also recently issued reports about the company. Morgan Stanley reissued an "overweight" rating and set a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Barclays reissued an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Piper Sandler reaffirmed an "overweight" rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Truist Financial raised their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $187.71.

Jazz Pharmaceuticals Trading Down 4.8 %

Shares of JAZZ traded down $6.77 during trading hours on Friday, hitting $135.25. 1,534,199 shares of the stock traded hands, compared to its average volume of 704,698. The business has a fifty day moving average of $131.79 and a 200-day moving average of $122.03. The firm has a market capitalization of $8.21 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Asset Management Inc acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $209,000. Natixis Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 7.6% during the 3rd quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company's stock worth $2,544,000 after acquiring an additional 1,603 shares in the last quarter. Swiss National Bank raised its holdings in shares of Jazz Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company's stock valued at $13,035,000 after purchasing an additional 400 shares during the last quarter. Advisors Asset Management Inc. lifted its position in shares of Jazz Pharmaceuticals by 3.9% in the third quarter. Advisors Asset Management Inc. now owns 9,624 shares of the specialty pharmaceutical company's stock worth $1,072,000 after purchasing an additional 364 shares in the last quarter. Finally, Foundry Partners LLC boosted its holdings in Jazz Pharmaceuticals by 10.9% during the third quarter. Foundry Partners LLC now owns 3,362 shares of the specialty pharmaceutical company's stock worth $375,000 after purchasing an additional 331 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Activity

In other news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares of the company's stock, valued at $966,323.72. This represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,022,825 in the last 90 days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.